Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 9—September 2010

Research

Pediatric Pneumococcal Serotypes in 4 European Countries

Germaine Hanquet1Comments to Author , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)

Main Article

Figure 2

Incidence of pediatric invasive pneumococcal disease among children 5–14 years of age, by heptavalent pneumococcal conjugate vaccine (PCV7) (black lines) and non-PCV7 (red lines) serotypes, A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006.

Figure 2. Incidence of pediatric invasive pneumococcal disease among children 5–14 years of age, by heptavalent pneumococcal conjugate vaccine (PCV7) (black lines) and non-PCV7 (red lines) serotypes, A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006.

Main Article

1Current affiliation: Belgian Healthcare Agency, Brussels, Belgium.

TOP